MACROGENICS, INC. Increase (Decrease) in Prepaid Expense and Other Assets
MACROGENICS, INC. (MGNX) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$1.18 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-14
- MACROGENICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$809.00K.
- MACROGENICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was -$374.00K.
- MACROGENICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $1.06M, a 87.96% increase year-over-year.
- MACROGENICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-06-30 was -$1.33M.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month |
|---|---|---|---|
| 2026-06-30 | -$809.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$1.18M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | -$374.00K 10-Q · filed 2026-05-13 | ||
| 2025-09-30 | $1.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$265.00K derived: sum of 2 quarters · filed 2026-08-14 | -$3.80M 10-Q · filed 2025-11-12 |
| 2025-06-30 | -$1.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$4.86M 10-Q · filed 2026-08-14 | |
| 2025-03-31 | -$3.54M 10-Q · filed 2026-05-13 | ||
| 2024-09-30 | $565.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$33.00K derived: sum of 2 quarters · filed 2025-11-12 | -$108.00K 10-Q · filed 2025-11-12 |
| 2024-06-30 | -$598.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$673.00K 10-Q · filed 2025-08-14 | |
| 2024-03-31 | -$75.00K 10-Q · filed 2025-05-13 | ||
| 2023-09-30 | $2.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | -$1.21M derived: sum of 2 quarters · filed 2024-11-05 | -$1.65M 10-Q · filed 2024-11-05 |
| 2023-06-30 | -$3.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$3.69M 10-Q · filed 2024-08-06 | |
| 2023-03-31 | -$443.00K 10-Q · filed 2024-05-09 | ||
| 2022-09-30 | -$3.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | -$5.44M derived: sum of 2 quarters · filed 2023-11-06 | -$11.90M 10-Q · filed 2023-11-06 |
| 2022-06-30 | -$2.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$8.61M 10-Q · filed 2023-08-09 | |
| 2022-03-31 | -$6.46M 10-Q · filed 2023-05-09 | ||
| 2021-09-30 | $106.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$159.00K derived: sum of 2 quarters · filed 2022-11-03 | $1.08M 10-Q · filed 2022-11-03 |
| 2021-06-30 | -$265.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $974.00K 10-Q · filed 2022-08-08 | |
| 2021-03-31 | $1.24M 10-Q · filed 2022-05-03 | ||
| 2020-09-30 | $2.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | -$2.00M derived: sum of 2 quarters · filed 2021-11-02 | -$654.00K 10-Q · filed 2021-11-02 |
| 2020-06-30 | -$4.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | -$3.09M 10-Q · filed 2021-07-29 | |
| 2020-03-31 | $1.34M 10-Q · filed 2021-04-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |